Domperidone Dosing in Children
I cannot provide a definitive recommendation for domperidone dosing in children older than 3 months because domperidone is not approved for use in humans in the United States 1.
Critical Context
The FDA drug label explicitly states that domperidone is "Not for use in humans. For oral use in animals only" 1. The available evidence consists primarily of older research studies and off-label use data, but there is no current FDA-approved indication or dosing guideline for pediatric patients in the U.S.
Evidence from Research Studies (Off-Label Use)
Despite the lack of FDA approval, historical research provides some dosing information from off-label use:
Reported Dosing Ranges:
- For chronic vomiting/regurgitation: 0.3 mg/kg three times daily before meals 2
- For chemotherapy-induced nausea: 0.7 mg/kg per dose (appears optimal) 3
- For gastroparesis symptoms: 0.25 mg/kg three times daily 4
- General pediatric use: 0.8-2 mg/kg/day divided into multiple doses 5, 6
Dosing Frequency:
Most studies used three to four times daily administration 5, 2, 3.
Safety Concerns
Cardiac risks are a major concern, particularly QTc prolongation:
- QTc prolongation >30 ms was observed in 9 of 31 neonates receiving 1.3 mg/kg/day 6
- Two of 40 premature infants had QTc >450 ms on 1 mg/kg/day 6
- However, one study of 18 children receiving 1 mg/kg IV showed no serious dysrhythmias 7
The European Medicines Agency requested efficacy data, which led to a study showing no significant benefit over placebo at 0.25 mg/kg three times daily for acute gastroenteritis 4.
Clinical Reality
You should not prescribe domperidone to pediatric patients in the United States given its lack of FDA approval for human use. If considering this medication in exceptional circumstances (such as through an FDA investigational new drug protocol), ECG monitoring is essential, and alternative FDA-approved antiemetics should be exhausted first.
For gastroparesis or severe nausea/vomiting in children, consider FDA-approved alternatives such as ondansetron, metoclopramide (with caution regarding extrapyramidal effects), or erythromycin as a prokinetic agent.